Ruta D. Rao, MD

Ruta D. Rao, MD, discusses how the updated National Comprehensive Cancer Network guidelines have influenced treatment selection for patients with HER2-positive breast cancer.

Ruta D. Rao, MD, an associate professor at Rush University Medical Center, discusses therapy de-escalation for patients with early-stage hormone receptor (HR)-positive, HER2-negative breast cancer.

Ruta D. Rao, MD, associate professor, Rush University Medical Center, discusses the results of the SOFT trial, presented at the 2017 San Antonio Breast Cancers Symposium.